Markets:

Overview

News

Currencies

International

Treasuries

Nektar Therapeutics - Common Stock (NQ:NKTR)

43.51 +0.54 (+1.26%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Nektar Therapeutics - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

NKTR Stock Earnings: Nektar Therapeutics Misses EPS, Beats Revenue for Q2 2024 ↗

August 08, 2024

NKTR stock results show that Nektar Therapeutics missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.

Via InvestorPlace

NKTR Stock Earnings: Nektar Therapeutics Meets EPS, Beats Revenue for Q1 2024 ↗

May 09, 2024

NKTR stock results show that Nektar Therapeutics met analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.

Via InvestorPlace

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

May 07, 2024

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

April 30, 2024

Via Benzinga

Sweet Nektar? ↗

April 22, 2024

NKTR has had a terrible time of it for years, but maybe it’s finally ready to turn around.

Via Talk Markets

Nektar Therapeutics Earnings Preview ↗

March 01, 2024

Via Benzinga

Recap: Nektar Therapeutics Q3 Earnings ↗

November 07, 2023

Via Benzinga

A Preview Of Nektar Therapeutics's Earnings ↗

November 06, 2023

Via Benzinga

Expert Ratings for Nektar Therapeutics ↗

May 10, 2023

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

April 11, 2024

Via Benzinga

Biotech's Lawsuit With Eli Lilly Might Catalyze Stock ↗

March 29, 2024

Nektar Therapeutics commenced a Phase 2b clinical trial evaluating its lead product candidate rezpegaldesleukin, in patients with severe to very severe alopecia areata, a disease-causing patchy hair...

Via Talk Markets

Topics Lawsuit

Why Bitdeer Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

March 04, 2024

Shares of Bitdeer Technologies Group (NASDAQ: BTDR) rose sharply during Monday’s session after the company reported preliminary fourth-quarter financial results, announced the successful testing of its...

Via Benzinga

Nektar Therapeutics: Q1 Earnings Insights ↗

May 09, 2023

Via Benzinga

Analyst Ratings for Nektar Therapeutics ↗

March 06, 2023

Via Benzinga

Earnings Scheduled For March 4, 2024 ↗

March 04, 2024

Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is estimated to report earnings for its fourth quarter.

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

January 12, 2024

Via Benzinga

The One-Minute Market Report - Saturday, Aug. 12 ↗

August 12, 2023

In this weekly outlook, I examine the asset classes, sectors, and ETFs that led the market higher, and which market segments bucked the trend by moving lower. Signs that market participation is...

Via Talk Markets

Topics ETFs

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

August 08, 2023

Via Benzinga

Nektar Therapeutics Earnings Perspective: Return On Capital Employed ↗

March 06, 2023

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

August 07, 2023

Via Benzinga

Why Krystal Biotech Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

August 07, 2023

Gainers Vistagen Therapeutics, Inc. (NASDAQ: VTGN) shares jumped 747.6% to $14.24 after the company announced its Phase 3 PALISADE-2 trial evaluating the efficacy, safety, and tolerability of...

Via Benzinga

Why Is Nektar Therapeutics Stock Surging Today? ↗

August 07, 2023

Nektar Therapeutics Inc (NASDAQ: NKTR) said its former partner Eli Lilly And Co (NYSE: LLY) had presented "erroneous data" from two Phase 1b studies of its atopic dermatitis drug,

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

August 07, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 10, 2023 ↗

May 10, 2023

Via Benzinga

Tempur Sealy International To Rally Around 32%? Here Are 10 Other Analyst Forecasts For Wednesday ↗

May 10, 2023

Keybanc raised the price target for Tempur Sealy International, Inc. (NYSE: TPX) from $48 to $50. Keybanc analyst Bradley Thomas maintained an Overweight rating. Tempur Sealy International shares rose...

Via Benzinga

Analyst Says Nektar Therapeutics' Rezpeg Prioritization Likely to Spark Investor Questions ↗

April 18, 2023

Via Benzinga

7 Sorry Pharma Stocks to Sell in April Before It’s Too Late ↗

April 16, 2023

You have to be patient when investing in pharma stocks. But sometimes the risk and the wait aren't worth the rewards.

Via InvestorPlace

Analysts At H.C. Wainwright & Co. Set 12-Month Target Of $15 Per Share For ENLV Thanks To High Profile Collaboration Agreement, Multiple Ongoing Clinical Trials ↗

April 13, 2023

This month, H.C. Wainwright & Co.

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

March 21, 2023

On Tuesday, 74 companies achieved new lows for the year.

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

March 14, 2023

Tuesday's morning session saw 84 companies set new 52-week lows.

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

READ OUR 2025 REPORT TO READERS

Nektar Therapeutics - Common Stock (NQ:NKTR)

All News about Nektar Therapeutics - Common Stock

The Newspapers of New England Family

We continue to need local support from our readers

Enjoying the Concord Monitor?

READ OUR 2025 REPORT TO READERS

Nektar Therapeutics - Common Stock (NQ:NKTR)

All News about Nektar Therapeutics - Common Stock

Sign in